Previous studies utilizing exenatide and liraglutide have demonstrated GLP-1 receptor agonists’ promising role in treating T1D, with evidence of weight loss, lower frequency insulin use, and improvements in glycemic control; however, further investigation is needed to better evaluate the benefits and risks of utilizing GLP-1 receptor agonists [110]. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.